RespireRx Pharmaceuticals Inc (fka RSPI)

[LTListener]

I would venture a guess it is primarily financial. I don't think they will return to markets until they can raise capital to clean up the cap table and be positioned for long-term sustainable support and advancement of the pipeline. In order to get there, they need significant valuation drivers to bring capital on board. Any additional NIH support (like the ADHD grant) would help. Obviously, IND enabling process is ongoing for KRM-ll-81. Who knows exactly how many boxes need checked in the "de-risking" process before major capital is unleashed.